Milea Timbergen

209 Supplementary Table 5. (continued) Kim et al. 43 (2016), Oncology Letters Salas et al. 49 (2010), Genes, Chromosomes & Cancer Nishida et al. 42 (2016), Oncology Letters Mullen et al. 20 (2013), The Oncologist Mussi et al. 41 (2016), Tumori Broekhoven et al. 22 (2015), Annals of Surgical Oncology Colombo et al. 23 (2013), Cancer Tumour site Head/neck NS NS 3 (23%) 4 (3%) NS 10 (10%) NS Chest wall / back NS NS 4 (31%) NS NS 23 (23%) NS Extremity NS NS NS 36 (31%) NS 26 (26%) NS Groin NS NS NS NS NS 4 (4%) NS Retroperitoneal NS NS NS NS NS 3 (3%) NS Abdominal wall 24 (15% ) d 39 (20%) 6 (46%) NS 33 (100%) 35 (35%) 75 (42%) j Trunk-superficial NS NS NS 43 (37%) NS NS NS Girdle NS NS NS 18 (16%) NS NS NS Intra-abdominal 19 (12%) 14 (7%) NS 14 (12%) NS 0 (0%) 32 (18%) Extra-abdominal (NS) 71 (45%) 132 (68%) NS NS NS NS 72 (40%) Superficial (fascial) Unknown 45 (28%) NS NS 9 (5%) NS NS NS NS NS NS NS NS NS NS Presentation Initial tumour 159 (100%) 112 (58%) NS 95 (83%) 31 (94%) 101 (100%) 179 (100%) Recurrent tumour 0 67 (35%) NS 20 (17%) 2 (6%) 0 0 Unknown - 15 (8%) 13 (100%) - - - - Mutation type S45F 13 (8.2%) 60 (33%) e 1 (8%) 29 (25%) 3 (12%) 18 (18%) 39 (22%) T41A 89 (56%) 70 (38%) e 6 (46%) 53 (46%) 9 (34%) 49 (49%) 81 (45%) Other 8 (5%) 20 (11%) e 0 (0%) 4 (4%) 1 (4%) 9 (9%) 11 (6%) Wild-type 48 (30.2%) 32 (18%) e 6 (46%) 29 (25%) 13 (50%) 25 (25%) 48 (27%) 7